Welcome to our dedicated page for Axsome Therapeut SEC filings (Ticker: AXSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Axsome Therapeutics, Inc. (NASDAQ: AXSM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a biopharmaceutical issuer focused on central nervous system (CNS) conditions, Axsome uses its SEC reports to communicate financial results, product revenue for AUVELITY, SUNOSI, and SYMBRAVO, and updates on its development pipeline, which includes programs such as AXS-05, AXS-12, AXS-14, solriamfetol in new indications, and AZD7325.
Among the filings, Form 8-K current reports are especially relevant for tracking material events. For example, Axsome has filed 8-Ks to furnish press releases announcing quarterly financial results and to disclose updates such as the receipt of a Paragraph IV Certification Notice Letter regarding a proposed generic version of SYMBRAVO. These documents help investors understand how clinical progress, intellectual property developments, and commercial performance affect the company.
In addition to 8-Ks, investors typically review Axsome’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain detailed discussions of net product revenue, research and development spending, selling and administrative expenses, risk factors, and descriptions of the company’s CNS portfolio and pipeline. Proxy statements and, when applicable, Forms 3, 4, and 5 can provide information on insider holdings and transactions, while registration statements and prospectuses outline capital-raising activities.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents such as 10-Ks, 10-Qs, and major 8-Ks in plain language. Real-time EDGAR updates help ensure that new Axsome filings appear promptly, and AI-generated highlights can make it easier to locate information on topics such as AXS-05’s regulatory status, AXS-12’s Orphan Drug Designation, or revenue trends for AUVELITY, SUNOSI, and SYMBRAVO without reading every page of the underlying filing.
Hunter R. Murdock, General Counsel of Axsome Therapeutics (AXSM), executed a series of pre-planned transactions under a 10b5-1 trading plan over three consecutive days from June 16-18, 2025.
The transactions followed a consistent pattern each day:
- Exercised 7,500 stock options at $29.91 per share
- Immediately sold 7,500 shares at weighted average prices between $100.26-$102.42
Total transaction summary:
- Exercised: 22,500 options
- Sold: 22,500 shares
- Remaining options: 29,883
- Net proceeds per share: approximately $70-72 (sale price minus exercise price)
These transactions were executed according to a pre-approved trading plan, which helps protect executives from insider trading allegations by establishing trade parameters in advance.
Form 144 Notice of Proposed Sale filed for Axsome Therapeutics (NASDAQ: AXSM) details insider trading activity. The filing indicates a proposed sale of 7,500 shares of common stock with an aggregate market value of $756,729, to be executed through Charles Schwab & Co.
The securities were acquired through an employee stock option exercise on June 18, 2025, with payment made via a cashless exercise through broker payment. The filing reveals recent trading activity by the same insider, Hunter R. Murdock, who sold:
- 7,500 shares on June 16, 2025, generating proceeds of $768,154
- 7,500 shares on June 17, 2025, generating proceeds of $751,975
The company currently has 49,236,365 shares outstanding. This Form 144 represents the seller's declaration that they are unaware of any material adverse non-public information regarding the company's operations.